Sialix Inc., a company looking to develop cancer and inflammatory disease treatments based on research conducted at the University of California San Diego, is opening an office in Kendall Square. The firm also disclosed an option agreement with Momenta Pharmaceuticals Inc., a biotechnology company also located Cambridge’s Kendall Square.

The financial details of the Momenta accord are not being disclosed, said Sialix chief executive Jeff Behrens, who will initially head up a two-person office at Dogpatch Labs, a collaborative workspace in Kendall Square underwritten by Polaris Venture Partners.

Behrens described Sialix as a “semivirtual” company — “a small core staff that relies on a network of advisers, consultants, and contract research organizations,” he said.


In a virtual company, nearly everything is outsourced, from clinical testing to manufacturing.

Sialix decided to open in Cambridge because the Boston area has a “phenomenal concentration of life sciences talent,” and because the state has demonstrated “terrific support of the industry,” Behrens said.

Chris Reidy